name: Allen Peng
profiles:
  - BSc (Pharm), MSc (Clin Pharm), MPH
  - 'Email: <a href="mailto:allen.peng08@gmail.com">allen.peng08@gmail.com</a>'
  - 'Phone: <a href="tel:+14438012670">443-801-2670</a>'
  - 'Quick links:
    <a href="https://www.linkedin.com/in/allen-peng-yl/" target="_blank">LinkedIn</a>'
bios:
  - Health economist and with 8 years of experience across a national health technology assessment (HTA) agency and global pharmaceutical companies. Proven ability to lead cross-functional teams and align stakeholders across medical, health economics & outcomes research (HEOR), and commercial functions to drive market access strategy. Skilled in cost-effectiveness analysis (CEA), budget impact modeling, and real-world evidence generation using SAS and R, with a strong track record of informing payer decisions and shaping policy. Recognized with Pfizer’s 2023 Global Best Practice Award for accelerating reimbursement and pricing approvals.

projects:
  - title: MSQ Ventures
    role: Healthcare Analyst Intern
    date: SEPT. 2025 – PRESENT
    thumbnail: "https://static1.squarespace.com/static/5707117b4c2f85d0ea6156e8/t/5e22892ec77df97290309f82/1579321649048/MSQ-logo-hires-2x1.png"
    descriptions:
      - Conducted scientific and market due diligence on 50+ biotech firms, including T cell therapy landscape analysis for Swarm Oncology, to identify cross-border partnership and investment opportunities
      - Developed 10+ pitch decks and pipeline evaluations supporting in/out-licensing and fundraising projects across the U.S., China, and Europe
      - Analyzed global biopharma market and capital trends, summarizing insights that informed prospect targeting and client engagement strategies
    links: {}

  - title: Pfizer
    role: Market Access Manager
    date: AUG. 2022 – MAY 2024
    thumbnail: "https://www.pfizer.com/profiles/pfecpfizercomus_profile/themes/pfecpfizercomus/public/assets/images/logo-blue.svg"
    descriptions:
    - Awarded 2023 Global Pfizer Best Practice - Access Acceleration for CIBINQO®
    - - Led access strategy that achieved reimbursement and pricing approval 6 months ahead of standard timeline, through close collaboration with global HEOR, commercial, medical, and public affairs teams
      - Secured listing price premiums through cost-effectiveness modeling, demonstrating compelling economic value to the national payer
    - Led cross-functional and external stakeholder alignment across regulatory, medical, commercial, and advocacy partners, ensuring launch readiness and public awareness for new immunology products and PCV20
    - Expanded reimbursement scope of atopic dermatitis by crafting value propositions that integrated unmet needs and clinical evidence, successfully negotiating with the national payer to broaden patient access
    - Developed simulation models to assess financial impact of biosimilar-favoring policies, enabling proactive mitigation strategies to protect branded biologics portfolio positioning
    links: {}

  - title: Novartis
    role: Senior Patient Access Specialist
    date: APR. 2020 – AUG. 2022
    thumbnail: "https://www.novartis.com/themes/custom/polaris/logo.svg"
    descriptions:
    - Developed CEA and pricing models across cardiovascular and respiratory portfolios, including Enerzair® , where the strategy led to a 2% price markup approved by the national payer
    - Conducted real-world outcomes research using Taiwan’s nationwide claims database (23 million lives) to demonstrate clinical benefits of Entresto® in heart failure care
    - Organized and led International HTA Workshop (100+ attendees), including Director-General and senior officers from the national payer and HTA agency, to strengthen policy dialogue and payer engagement
    - Co-authored policy white papers on cardiovascular disease management, enhancing payer education and disease awareness - "Shaping Cardiovascular Disease Access Policy Landscape"
    links:
      "Shaping Cardiovascular Disease Access Policy Landscape": "https://www.iqvia.com/locations/asia-pacific/library/white-papers/shaping-cvd-policy-landscape-in-taiwan-english"

  - title: Center for Drug Evaluation
    role: HTA Researcher in Economic Team
    date: MAR. 2017 – APR. 2020
    descriptions:
    - Conducted 20+ CEAs and budget impact analysis annually and authored HTA reports for new drug reimbursement applications, informing payer decisions and enabling access for 600,000+ patients
    - Developed Horizon Scanning system to support national payer in proactive budget planning and allocation
    - Accelerated pneumococcal vaccine policy implementation in high-risk populations by evaluating clinical outcomes and cost-effectiveness, informing national rollout decisions
    - Facilitated Pharmacoeconomics Workshops for pharmaceutical professionals, delivering theoratical and hands-on training on CEA model development using TreeAge and Excel
    - Published HEOR studies and presented findings at international conferences (HTAsiaLink, ISPOR Asia), showcasing analytical and effective scientific communication.
    links: {}

  - title: Kaohsiung Chang Gung Memorial Hospital
    role: Assistant Researcher
    date: SEPT. 2016 – MAR. 2017
    descriptions:
    - Performed real-world data analysis using SAS on hospital electronic medical records (EMR), including data cleaning, regression modeling, and statistical interpretation
    - Authored a propensity-score matched cohort study examining renal protection effects of medications hyperuricemia patients, contributing to evidence-based clinical recommendations
    - Conducted EQ-5D interviews with pediatric CKD patients as part of a quality-of-life study, also leading IRB submission preparations and developing study protocol to ensure ethical and methodological rigor
    - Participated in the national EQ-5D-5L validation study in Taiwan (Lin et al., 2018), assisting with survey implementation and data quality monitoring across diverse population groups
    links: {}
publications: []

